RenovoRx (RNXT)
NASDAQ:RNXT
Want to see RNXT full AI Analyst Report?
RNXT Stock Chart & Stats
$1.00
-$0.05(-3.65%)
At close: 4:00 PM EST
$1.00
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.70 - $1.45
Previous CloseN/A
Volume39.72K
Average Volume (3M)288.82K
Market Cap
$39.71M
Enterprise Value$20.53M
Total Cash (Recent Filing)$12.36M
Total Debt (Recent Filing)$78.00K
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 13, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding45,052,708
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue13.79
Enterprise Value/Gross Profit17.52
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$6.88Price Target Upside587.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$3.25M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionEarly commercial adoption of RenovoCath at multiple cancer centers and plans to convert clinical trial sites into commercial customers could expand device sales as clinical teams become familiar with the technology.
Pivotal Trial ProgressAn independent data monitoring committee's decision to continue the Phase 3 RenovoGem registration trial after an interim review signals confidence in the study's conduct and supports potential regulatory advancement.
Regulatory Clearance And Differentiated PlatformThe FDA-cleared dual-balloon RenovoCath and its trans-arterial micro-perfusion delivery approach offer a differentiated method to deliver chemotherapy directly to poorly perfused tumors, which could improve outcomes and enable premium pricing if broadly adopted.
Bears Say
Clinical-stage Financial RiskRemaining a clinical-stage company with limited current revenues exposes the business to high development and commercialization risks, increasing the likelihood of funding needs or dilution.
Revenue ShortfallQuarterly revenue falling short of analyst expectations highlights that near-term sales traction remains uneven and may pressure investor confidence in revenue visibility.
Uneven Early CommercializationEarly commercialization revenue may be modest and uneven as cancer centers gradually adopt the catheter, creating risk to steady revenue growth while commercial momentum builds.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $1.45 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $39.71M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Aug 13, 2026 which is in 81 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on May 14, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.01.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.07.
How many shares outstanding does RenovoRx have?
RenovoRx has 45,052,708 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -4.094%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.88 (587.50% Upside)
$6.88 (587.50% Upside)
Insider Transactions
Bought Shares
Worth $19.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.27%
12-Months-Change
Fundamentals
Return on Equity
-138.61%
Trailing 12-Months
Asset Growth
-12.80%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RNXT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful operational milestones: record quarterly revenue with very high gross margins, rapid expansion of active centers and a sizable prospect pipeline, near-completion of the pivotal Phase III trial, and a successful $10M private placement providing runway into H2 2027. Offsetting factors include still-modest absolute revenue, sizable operating expenses (R&D $1.2M; SG&A ~$2.7M), remaining trial and event targets to achieve, and timing/convertibility risk of pipeline centers. Overall the positive execution on commercial scaling, healthy margins, and a reinforced balance sheet materially outweigh the near-term risks described.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$6.88
▲(587.50% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.34% Insiders
3.91% Mutual Funds
12.96% Other Institutional Investors
76.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---